Product Efficacy
Efficacy and Tolerability Study of BTXA™ Treatment in Patients with Facial Wrinkles
An open-label, prospective, multicenter and multidisciplinary phase III study was carried out in Brazil. 110 patients with facial wrinkles were recruited into the study for 180 consecutive days.
98% of patients are satisfied in using BTXA™.
- The satisfactory rate reached more than 90% in 14 days after injection
- 50% patients maintained satisfactory result up to 6 month period4
- Only 1 % of the patients reported pain or burning sensation upon the injection and no patients reported significant post-injection pain4
Efficacy and Tolerability Study of BTXA™ Treatment in Patients with Facial Wrinkles
An open-label, prospective, multicenter and multidisciplinary phase III study was carried out in Brazil. 110 patients with facial wrinkles were being studied continuously for 180 days
- The satisfactory rate reach more than 90% in 14 days after injection
- 50% patients maintained satisfactory result up to 6 month period4
- Only 1 % of the patients reported much pain or burning upon the injection and no patients report significant post-injection pain4
- Costa J, Rieder C, et al. A double-blind, randomised, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007;30:39-42
- Drug Safety Report-Prosigne® (Botulinum Toxin Type A), Jan 2009, Hugh Source (Int'l) Ltd. Data on file
- 2007 American Society of Aesthetic Plastic Surgery (ASAPS) Cosmetic Surgery National Data Bank Statistics.
- Talarico S, Bgatin E, Pecora CS, Ferreira LM, Orofino R, Godoy A, et al. Open-label, prospective, multicenter, multidisciplinary Phase III Study to evaluate the efficacy and tolerability of Prosigne® (Botulinum Toxin Type A) in the aesthetic treatment of the upper third of the face in patients with facial wrinkles. Data on file.
